Literature DB >> 7621848

Estimation of the absolute bioavailability of flecainide using stable isotope technique.

K Hage1, K Bühl, C Fischer, N G Knebel.   

Abstract

Data on the absolute bioavailability of flecainide are controversial. We have investigated whether differences in metabolic clearances and/or the absorption profile might be responsible for the variability in its absolute bioavailability. Six subjects with a wide range of flecainide metabolic clearances (85-407 ml.min-1) simultaneously received the drug by the IV and oral routes; the oral dose was labelled with deuterium. Besides estimation of absolute bioavailability, this design permitted assessment of metabolic clearance after IV and oral administration, and absorption could be assessed from the urinary excretion of labelled and unlabelled drug and metabolites. The absolute bioavailability of flecainide ranged from 79.9 to 101.1% (mean 93.6%). The absorption was 86.1 to 101.3% (mean 93.2%). The data indicate that the variable bioavailability of flecainide is due both to metabolism and absorption. The study highlights the potential of stable isotope technique in the investigation of such issues.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7621848     DOI: 10.1007/bf00202172

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

1.  Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH.

Authors:  A S Gross; G Mikus; C Fischer; M Eichelbaum
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification.

Authors:  M Heim; U A Meyer
Journal:  Lancet       Date:  1990-09-01       Impact factor: 79.321

Review 3.  Drug therapy. Flecainide.

Authors:  D M Roden; R L Woosley
Journal:  N Engl J Med       Date:  1986-07-03       Impact factor: 91.245

4.  Is there a genetic factor in flecainide toxicity?

Authors:  J Beckmann; R Hertrampf; U Gundert-Remy; G Mikus; A S Gross; M Eichelbaum
Journal:  BMJ       Date:  1988-11-19

5.  Simultaneous assessment of the intravenous and oral disposition of the enantiomers of racemic nimodipine by chiral stationary-phase high-performance liquid chromatography and gas chromatography/mass spectroscopy combined with a stable isotope technique.

Authors:  C Fischer; F Schönberger; W Mück; K Heuck; M Eichelbaum
Journal:  J Pharm Sci       Date:  1993-03       Impact factor: 3.534

6.  Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology.

Authors:  E J Ariëns
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype.

Authors:  A S Gross; G Mikus; C Fischer; R Hertrampf; U Gundert-Remy; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

8.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

Review 9.  Metabolism of flecainide.

Authors:  G J Conard; R E Ober
Journal:  Am J Cardiol       Date:  1984-02-27       Impact factor: 2.778

10.  Superiority of stable isotope techniques in the assessment of the bioavailability of drugs undergoing extensive first pass elimination. Studies of the relative bioavailability of verapamil tablets.

Authors:  M Eichelbaum; H J Dengler; A Somogyi; G E von Unruh
Journal:  Eur J Clin Pharmacol       Date:  1981-01       Impact factor: 2.953

View more
  4 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects.

Authors:  Sijie Lu; R A Nand; J S Yang; Gang Chen; A S Gross
Journal:  Eur J Clin Pharmacol       Date:  2017-11-27       Impact factor: 2.953

Review 3.  Applications of stable isotopes in clinical pharmacology.

Authors:  Reinout C A Schellekens; Frans Stellaard; Herman J Woerdenbag; Henderik W Frijlink; Jos G W Kosterink
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

4.  Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation.

Authors:  N J Alp; J A Bell; M Shahi
Journal:  Heart       Date:  2000-07       Impact factor: 5.994

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.